# US 2022/0073932 A1 · Antisense oligonucleotides for allele specificity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0073932 A1
- Document ID: US20220073932A1
- Status: Published application
- Kind: A1
- Application number: 17/478,293
- Filed: 2021-09-17
- Published: 2022-03-10
- Earliest claimed: 2019-03-21
- Assignees: ARNAY Sciences LLC
- Applicants: ARNAY Sciences LLC
- Inventors: Sudhir Agrawal
- Web page: https://patentgrep.com/patent/US20220073932A1

## CPC

- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N 2310/314: Phosphoramidates
- C12N 2310/315: Phosphorothioates
- C12N 2310/342: Hemimers, i.e. of the type ====----
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2320/34: Allele or polymorphism specific uses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides an antisense oligonucleotide compound 17 to 25 nucleotides in length comprising at least 12 contiguous nucleobases complementary to an equal length portion of a target RNA sequence, wherein the antisense oligonucleotide compound comprises a 3′ domain and a 5′ domain, wherein the 3′ domain is 10 to 12 nucleotides in length and each nucleotide comprises a deoxyribonucleotide and a phosphodiester or phosphothioate internucleotide linkage or combinations thereof, and wherein the 5′ domain is 5 to 15 nucleotides in length, and wherein the 5′ domain comprises unmodified deoxyribonucleotides, unmodified ribonucleotides, modified deoxyribonucleotides, modified ribonucleotides, or combinations thereof, provided that the 5′ domain comprises at least 1 modified deoxyribonucleotide or modified ribonucleotide comprising a modified sugar and/or backbone. The invention further provides methods of using the antisense oligonucleotide compounds as described herein.

## Claims

### Claim 1

An antisense oligonucleotide compound 17 to 25 nucleotides in length comprising at least 12 contiguous nucleobases complementary to an equal length portion of a target RNA sequence, wherein the antisense oligonucleotide compound comprises a 3′ domain and a 5′ domain, which is contiguous with the 3′ domain,
wherein the 3′ domain is 10 to 12 nucleotides in length and each nucleotide comprises a deoxyribonucleotide and a phosphodiester or phosphothioate internucleotide linkage or combinations thereof; and
wherein the 5′ domain is 5 to 15 nucleotides in length, and wherein the 5′ domain comprises unmodified deoxyribonucleotides, unmodified ribonucleotides, modified deoxyribonucleotides, modified ribonucleotides, or combinations thereof, provided that the 5′ domain comprises at least 1 modified deoxyribonucleotide or modified ribonucleotide comprising a modified sugar and/or backbone.

### Claim 2 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein the 3′ domain is 12 nucleotides in length and comprises nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 from the 3′ end.

### Claim 3 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein the 3′ domain is 11 nucleotides in length and comprises nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 from the 3′ end.

### Claim 4 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein the 3′ domain is 10 nucleotides in length and comprises nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 from the 3′ end.

### Claim 5 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein the nucleotides of the 3′ domain comprise a natural nucleobase.

### Claim 6 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein at least one of the nucleotides of the 3′ domain comprises a modified nucleobase.

### Claim 7 (depends on 6)

The antisense oligonucleotide according to claim 6, wherein the nucleotides at the 9th or 10th positions are not modified.

### Claim 8 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein the nucleotide at the 11th position is not modified.

### Claim 9 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein the oligonucleotide comprises at least one phosphorothioate internucleotide linkage.

### Claim 10 (depends on 9)

The antisense oligonucleotide according to claim 9, wherein at least half of the internucleotide linkages are phosphorothioate.

### Claim 11 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein the antisense oligonucleotide is single stranded.

### Claim 12 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein the 5′ domain comprises at least 1 modified deoxyribonucleotide or modified ribonucleotide comprising a modified sugar.

### Claim 13 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein the 5′ domain comprises at least 1 modified deoxyribonucleotide or modified ribonucleotide comprising a nonphosphorus-based backbone.

### Claim 14 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein at least three of the nucleotides of the 5′ domain are modified with a deoxyribonucleotide or modified ribonucleotide comprising a modified sugar and/or backbone.

### Claim 15 (depends on 1)

The antisense oligonucleotide according to claim 1, further comprising a 5′ blocking agent.

### Claim 16 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein the antisense oligonucleotide is at least 90% complementary over its entire length to a portion of the target RNA.

### Claim 17 (depends on 1)

The antisense oligonucleotide according to claim 1, wherein the target RNA may be an mRNA, pre-mRNA. ncRNA, or microRNA.

### Claim 18 (depends on 17)

The antisense oligonucleotide according to claim 17, wherein the target RNA is mRNA.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising the antisense oligonucleotide according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1, 19)

A method for inhibiting gene expression comprising administering an antisense oligonucleotide according to claim 1 or a composition according to claim 19, wherein the antisense oligonucleotide is complementary to a nucleotide sequence of a target RNA.

### Claim 21 (depends on 1, 19)

A method for inhibiting allele-specific gene expression comprising administering an antisense oligonucleotide according to claim 1 or a composition according to claim 19, wherein the antisense oligonucleotide is complementary to a nucleotide sequence of a target allele RNA.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the target allele comprises a point mutation.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the antisense oligonucleotide compound comprises a sequence complementary to a region of the target allele RNA encoding a point mutation and wherein the nucleotide within the antisense oligonucleotide complementary to the point mutation is located at the 9th, 10th or 11th nucleotide position from the 3′ end of the antisense oligonucleotide.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the antisense oligonucleotide compound comprises a sequence complementary to a region of the target allele RNA encoding a point mutation and wherein the nucleotide within the antisense oligonucleotide complementary to the point mutation is located at the 9th or 10th nucleotide position from the 3′ end of the antisense oligonucleotide.

### Claim 25

(canceled)

### Claim 26 (depends on 20)

The method according to claim 20, wherein in the method is useful for treating a subject having disease or disorder wherein inhibiting expression of a gene would be beneficial.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the disease or disorder results from abnormal expression or product of a cellular gene.

### Claim 28 (depends on 20)

The method according to claim 20, wherein the antisense oligonucleotide is administered locally.

### Claim 29 (depends on 21)

The method according to claim 21, wherein in the method is useful for treating a subject having disease or disorder wherein inhibiting expression of a gene would be beneficial.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the disease or disorder results from abnormal expression or product of a cellular gene.

### Claim 31 (depends on 21)

The method according to claim 21, wherein the antisense oligonucleotide is administered locally.
